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ABSTRACT 
Objective: The present research aims to design and optimize gastroretentive floating pellets of anagliptin (a dipeptidyl peptidase-4 inhibitor), so as 
to reduce P-Glycoprotein (PGP)–mediated efflux in the intestine hence to improve oral bioavailability. 
Methods: The drug-containing core pellets were prepared by extrusion and spheronization process followed by subsequent coating with three 
successive layers i.e. Eudragit RS 100, sodium bicarbonate (NaHCO3): hydroxypropyl methylcellulose E5LV (HPMC E5LV) and Eudragit RL 100 
using fluidized bed processor. A 3 level 3 factor box-behnken design was adopted to investigate the effect of Eudragit RS 100, NaHCO3
Results: The study reveals the significant effect of the amount of NaHCO
: HPMC 
E5LVand Eudragit RL 100 on floating lag time and drug release at 10 h. Desirability function under numerical optimization technique was used to 
identify the optimum formulation.  
3
Conclusion: The gastroretentive floating pellets of anagliptin was obtained and could be a promising technique to deliver anagliptin with improved 
bioavailability in the management of the metabolic syndrome.  
 and coating level of polymers on floating lag time and drug release. The 
optimum system could float within 4 min and exhibited more than 85% drug release in 10 h. The pharmacokinetic study conducted in male Wistar 
rats indicated 2.51 fold increase in relative bioavailability of optimized formulation compare to anagliptin drug. Formulated anagliptin pellets were 
evaluated in cafeteria diet-induced metabolic syndrome model in male Wistar rats. Anagliptin floating pellets treatment compared to cafeteria diet 
group significantly inhibited increase in body weight (238.79±2.52 g vs. 277.98±3.69 g, P<0.001), calorie intake (2283.99 kcal vs. 3086.05 kcal, 
P<0.05) and serum levels of total cholesterol (95.19±0.61 mg/dl vs. 110.04±1.31 mg/dl, P<0.01), triglycerides (96.12±1.25 mg/dl vs. 105.99±1.29 
mg/dl, P<0.01) while high-density lipoproteins levels were improved (42.15±0.92 mg/dl vs. 30.92±0.77 mg/dl, P<0.01) indicated its hypophagic 
and anti-hyperlipidemic effects.  
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The urbanization and sedentary lifestyles of 21st
In the present investigation, a floating multiparticulate drug delivery 
system of anagliptin based on effervescent technique was developed. 
The drug-containing core pellets were prepared using extrusion and 
spheronization process. The drug-loaded pellets were coated with three 
successive layers, internal coat of Eudragit RS 100 as release retardant 
followed by effervescent layer coat (NaHCO
 century leads to 
increase the prevalence of metabolic syndrome and is becoming a major 
public health concern. Metabolic syndrome includes the number of 
chronic disease such as insulin resistance, obesity, dyslipidemia, cardio-
metabolic risk and hypertension [1]. Patient compliance becomes an 
issue in the management of metabolic syndrome, due to the use of 
multiple drugs and risk of enhanced drug-drug interactions [2]. 
Identifying drug candidates exhibiting polypharmacology could be one of 
the strategies favourable to deal with multifactorial diseases [3]. 
Anagliptin a dipeptidyl peptidase 4 (DPP4) inhibitor, besides their 
glucose-lowering activity, is a promising drug candidate for management 
of multifactorial diseases constituting metabolic disorders [4]. However, 
systemic bioavailability of anagliptin is limited by PGP mediated efflux in 
the intestine [5]. PGP, a plasma membrane-bound ATP-dependent efflux 
transporter, is a well-recognized factor that can influence drug 
pharmacokinetics [6]. In addition, anagliptin has a shorter biological half-
life of 3-4 h. It is needed to improve the oral bioavailability of anagliptin 
to be effectively used in many clinical applications. The conventional 
controlled-release technologies are not suitable for the delivery of PGP 
substrates because they carry a significant part of the drug to distal 
regions of the gastrointestinal tract (GIT). On the other hand, continuous 
delivery to the proximal part of the GIT, as provided by gastroretentive 
dosage forms, might be useful for these drugs [7-9]. Various approaches 
have been reported to retain the formulation in the upper part of GIT 
such as swelling systems, high-density systems, magnetic systems, 
mucoadhesive systems and floating systems [10]. Among all the 
gastroretentive systems, due to minimum effect on GIT motility, floating 
drug delivery systems (FDDS) are considered suitable and preferable 
[11-13]. These systems are particularly useful for drugs having 
absorption in upper GIT, drugs which are unstable in the intestine and 
exhibits poor solubility in intestinal pH [14]. FDDS are low density 
system which allows them to remain buoyant over gastric content for 
prolonged period of time [15]. Based upon the mechanism of buoyancy 
effervescent systems are the widely employed technique used in the 
development of FDDS. In the effervescent systems, carbon dioxide gas 
liberation occurs upon contact with gastric fluid due to neutralization 
reaction which lowers the density and allows the system to remain 
buoyant [16]. A wide range of single unit and multiparticulate FDDS 
were designed and developed, the multiparticulate FDDS were preferred 
over single unit system due to reduce inter and intra subject variabilities 
in drug absorption and lower possibility of dose dumping [17-19]. 
Designing sustained release multiparticulate drug delivery system of 
anagliptin with prolonged residence time in the stomach using FDDS 
approach can significantly improve the overall bioavailability.  
3
MATERIALS AND METHODS 
: HPMC E5LV); and top coat 
of Eudragit RL 100 as a gas entrapped polymeric membrane. The effect 
of the amount of effervescent agent and coating level of polymeric 
membrane on floating ability and drug release properties were studied 
and optimized using response surface methodology.  
Materials 
Anagliptin was obtained as gift sample from Wockhardt Limited, 
Aurangabad, India. Eudragit RL 100 and Eudragit RS 100 were provided 
by Evonik Pharma, Mumbai, India. Sodium bicarbonate, Hydroxypropyl 
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methylcellulose E5LV, Microcrystalline cellulose, polyvinylpyrrolidone 
K30 obtained from Himedia Laboratories, Mumbai, India. All the other 
reagents used in the study were of analytical grade. 
Preparation of gastroretentive floating pellets 
Preparation of drug loaded pellets 
The anagliptin containing core pellets were prepared using wet 
granulation method by extrusion and spheronization technique. 
Powder mixture of anagliptin (40% w/w) and spheronizing aid 
(microcrystalline cellulose 60% w/w) was mixed uniformly in 
mortar for 20 min. This was followed by the addition of binding 
liquid (0.5% w/v polyvinylpyrrolidone K30 in distilled water) into 
the dry powder mixture. Binding liquid was incorporated into the 
pelletization process to get damp mass and to obtain sufficient 
hardened pellets suitable for the subsequent coating process. The 
prepared damp mass was passed through BSS sieve no.16 to get the 
extrudates. Extrudates were then transferred to spheronizer (Shakti 
Pharmatech, Ahmedabad, India) and spheronized at 900rpm for 
about 10 min to obtain the pellets. The drug-loaded core pellets 
were oven dried overnight at 40○
The drug-loaded pellets were coated with three successive layers, 
release retardant Eudragit RS 100 as internal coat followed by 
effervescent layer (NaHCO
C. 
Coating of drug loaded pellets 
3: HPMC E5LV) and gas entrapped 
Eudragit RL 100 as top coat. The Eudragit RS 100 coating solution 
was prepared by dissolving it into isopropyl alcohol (10 % w/w 
solid content) plasticized with 10 % triethyl citrate (w/w based on 
polymer solid) and stirred to obtain a clear solution. The coating 
process was conducted in fluidized bed processor (ACG, Miniquest-F, 
Mumbai, India), to obtain predetermined weight gain of 5%, 10% 
and 15% w/w. The coating conditions were batch size, 10 g; inlet 
temperature, 40○C; product temperature, 35○ C; air flow, 0.8–1.0 bar; 
spray pressure, 0.5–0.9 bar; spray rate, 4-5 ml/min and final drying 
at 40○C for 15 min. The Eudragit RS 100 coated pellets were further 
coated with effervescent layer coating. The required amount of 
NaHCO3 was dispersed in HPMC E5 LV solution 10 % w/w solid 
content in the ratio of 2:1, 1:1 and 1:2 (w/w), plasticized with 10 % 
Polyethylene glycol 6000 (w/w based on polymer solid). The 
effervescent layer coating was done to obtain a fixed weight gain of 
10% w/w. The coating conditions were temperature, 40○±5○C; air 
flow, 0.8–1.0 bar; spray pressure, 0.5–0.9 bar; spray rate, 1–1.5 
ml/min. The obtained effervescent layered coated pellets were dried 
at 40○
Experimental design  
C for 30 min. Finally, Eudragit RL 100 coating solution prepared 
in Isopropyl alcohol (10 % w/w solid content) plasticized with 10 % 
triethyl citrate (w/w based on polymer solid) coated over effervescent 
layered pellets. During coating the predetermined weight gain 
obtained was 5%, 10% and 15% w/w. The coating conditions were 
the same as kept during coating of Eudragit RS 100 mentioned above. 
The formulation batches prepared are indicated in table 2. 
A 3-level, 3-factor, 13 run experiment box-behnken design was 
adopted for optimization of gastroretentive floating pellets 
formulations. The selected independent variables were the 
concentration of Eudragit RS 100 (X1), the ratio of NaHCO3
 
: HPMC 
(X2) and Eudragit RL 100 concentration (X3). The levels of 
independent variables are shown in (table 1). The dependent 
variables taken as a response were floating lag time (Y1) and 
percent drug release in 10 h (Y2). The experimental formulations 
composition indicated in (table 2). Response surface modelling, 
ANOVA and model graphs studies were carried out employing 
Design-expert® software (Version10, Stat-Ease). 
Table 1: Levels of independent variables in experimental design 
Factors Coded value Actual value 
Low Medium High Low Medium High 
Eudragit RS 100 (%)-X1 -1 0 +1 05 10 15 
NaHCO3 -1 : HPMC (%)-X2 0 +1 1:2 1:1 2:1 
Eudragit RL 100 (%)–X3 -1 0 +1 05 10 15 
 
Table 2: Experimental formulation composition 
Batch No. Eudragit RS 100 (%) NaHCO3 Eudragit RL 100 (%) : HPMC (%) 
F 1 10 2:1 15 
F 2 10 1:1 10 
F 3 05 1:1 15 
F 4 05 1:1 05 
F 5 10 1:2 05 
F 6 05 2:1 10 
F 7 05 1:2 10 
F 8 15 1:2 10 
F 9 15 1:1 15 
F 10 10 2:1 05 
F 11 15 2:1 10 
F 12 10 1:2 15 
F 13 15 1:1 05 
F 14 05 2:1 05 
 
The desirability approach was used in Design-expert® software to 
find the optimum level of independent variables, to gainsay the 
reliability suggested new formulation was prepared (batch F 14).  
Evaluation of gastro retentive floating pellets 
Physical characterization 
The micromeritic properties (Carr’s index, Hausner’s ratio and angle 
of repose) were determined to evaluate the flow properties of 
floating pellets. Friability of the pellet formulations was determined 
using friabilator (Veggo Friability Tester, India). 10 g of core pellets 
were kept into friabilator and the percentage weight loss after 200 
revolutions was determined to calculate friability [20-23]. 
Pellet sphericity 
Pellets sphericity was determined in terms of aspect ratio [24]. Feret 
diameter and perpendicular diameter of the pellet were measured 
using digital vernier calliper (Mitutoyo, Japan). The aspect ratio of 
pellets was calculated with the following equation:  
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Determination of the drug content  
The drug content in the floating pellets formulation was determined 
by extraction with 0.1 N HCl. Pellets equivalent to about 200 mg of 
anagliptin were accurately weighed, ground and transferred into a 
volumetric flask containing 0.1 N HCl. The mixture was sonicated for 
30 min to ensure complete extraction of the drug. The solution was 
further filtered, diluted with an appropriate amount of 0.1 N HCl and 
assayed spectrophotometrically at 248.5 nm (Shimadzu, 1700, 
Japan). The analysis was performed in the range of 0-10 μg/ml 
where Beer’s law was obeyed for anagliptin. 
Scanning electron microscopy (SEM) 
The surface morphology of the uncoated pellets, Eudragit RS 100 
coated, effervescent layer coated and Eudragit RL 100 coated pellets 
were examined under the scanning electron microscope (Jeol, 
Oxford Instrument, United Kingdom). The pellet samples were 
sputter coated with gold/Palladium mixture for 1 min under an 
argon atmosphere and placed into a scanning electron microscope 
chamber. The photomicrograph of the pellets was obtained at 20 kV 
accelerating voltage. 
Floating studies 
The floating studies were conducted using USP Type–II dissolution 
apparatus (Veego DA-8D, India) in 900 ml of 0.1 N HCl maintained at 
37°C±0.5° C. The medium was agitated by paddle at 50 rpm into 
which coated pellets (100) were placed [25-27]. The time taken by 
the pellets to rise over the surface of the medium (floating lag time) 
was measured visually (n=3). The floating pellets percentage at 10 h 
was also determined by the equation indicated below:  
Floating pellets (%) = No.of floating pellets at measure time
Initial no.of pellets
×100 
In vitro drug release study 
In vitro drug release study of anagliptin (uncoated and coated pellet 
formulations) was determined in triplicates using USP Type–II 
dissolution apparatus (Veego DA-8D, India). The dissolution medium 
used was 900 ml of 0.1 N HCl. Pellets equivalent to 200 mg of 
anagliptin were accurately weighed and transferred into dissolution 
medium kept at 37°C±0.5° C on 50 rpm. At predetermined time 
intervals, 5 ml of aliquots were withdrawn and immediately 
replaced by the same volume of fresh medium to maintain the sink 
condition. The aliquots were filtered and analyzed by UV 
spectrophotometer at 248.5 nm to calculate the drug release.  
To understand the mechanism of drug release kinetics from 
optimized floating pellets formulation, the obtained drug release 
data were analyzed according to the mathematical models like zero-
order model, first-order model, Higuchi model and Korsmeyer-
Peppas model [28-32]. 
Statistical data analysis and optimization 
The obtained data of responses (floating lag time and percentage 
drug release at 10 h) for all formulations were analyzed by Design-
expert® software. Polynomial models for all the response variables 
including linear, interaction and quadratic terms were generated. 
The suggested model based upon the values of standard deviation, 
multiple correlation coefficient (R2) and adjusted multiple 
correlation coefficient (adjusted R2
Stability studies  
) was selected [33]. The selected 
model was further analyzed by analysis of variance (ANOVA) to 
determine significant model terms. The P value, lack of fit value, 
regression equation of the responses, diagnostic plot (Actual vs 
Predicted) and response surface plots were also generated using the 
software. The generated response surface plots were studied to 
understand the relationship between the dependent and 
independent variables. Finally, a numerical optimization technique 
based upon desirability approach was used to determine the 
optimum level of independent variables for the formulation. 
The accelerated stability study of anagliptin floating pellet 
formulation was performed as per ICH guidelines. The pellet sample 
was stored in 10 ml open glass vials at 40° C/75% relative humidity 
for three months. Pellet sample was observed for drug content, drug 
release at 10 h and any change in physical appearance after first, 
second and third month [34]. 
In vivo pharmacokinetics-study design  
In vivo pharmacokinetics studies were conducted in male Wistar rats 
after obtaining approval from the Institutional Animal Ethical 
Committee (DYPIPSR/IAEC/MAY/17-18/P-16). The study was aimed 
to compare the formulated anagliptin floating pellets with anagliptin 
plain drug. Twelve wistar rats weighing 180–200 g were separated 
randomly into two groups and fasted overnight with free access to 
water. Anagliptin floating pellets (200 mg/kg) and anagliptin plain 
drug (200 mg/kg) were administered orally into respective groups. At 
predetermined time intervals (0.25, 0.5, 1, 2, 4, 8, 12, and 24 h) post 
oral dose, 0.5 ml of blood samples were collected by the retro-orbital 
method. Plasma was immediately separated by centrifuging at 4000 
rpm for 15 min and stored at–20 °C until analysis.  
HPLC analysis of anagliptin in plasma  
Plasma concentrations of anagliptin were determined by HPLC 
method [5]. To 0.1 ml of plasma sample, 0.9 ml of acetonitrile was 
added and centrifuged for 15 min at 10000 rpm. The supernatant 
liquid obtained after centrifugation was filtered through 0.2 μ filter 
followed by injection of 20 μl into the system. The chromatography 
was carried out on a reversed-phase HPLC column (Kromasil, 4.6 x 
250 mm, 5 um, Shreetech Associates; Mumbai, India) using 
Shimadzu HPLC LC20 AD (Shimadzu Corporation, Japan). The 
mobile phase consisted of acetonitrile and ammonium acetate buffer 
pH 4.5 (50:50). The eluate was analyzed at a wavelength of 248 nm 
with a flow rate of 0.8 ml/min.  
Pharmacokinetic analysis  
Required pharmacokinetic parameters were calculated using PK solver 
software (version 2.0). Peak plasma concentration (Cmax), time to reach 
peak plasma levels (Tmax), area under the curve (AUC), mean residence 
time (MRT), half-life (t1/2), elimination constant (Kel) and relative 
bioavailability were estimated. The calculated pharmacokinetic 
parameters of both anagliptin floating pellets and plain drug were 
statistically analyzed using ANOVA and the difference less than the 
probability level 0.05 was considered statistically significant. 
 
Table 3: Calorie value of the cafeteria diet 
Ingredients Calorie Value (Kcal/100g) 




Dried Coconut 185 
Cheese 402 
Boiled Potato 75 
 
Pharmacodynamic study in cafeteria diet-induced metabolic 
syndrome model  
The male Wistar rats (180–200 g) were procured from National 
Institute of Bio-science, Pune, Maharashtra, India. The animals were 
housed under controlled room temperature and humidity condition 
with 12 h light and 12 h dark cycle. The animals were provided free 
access to food and water. After one week of acclimatisation period, 
animals were used for the study. The experimental protocol was 
approved by the Institutional Animal Ethical Committee 
Mishra et al. 
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(DYPIPSR/IAEC/MAY/17-18/P-17). In the present study cafeteria 
diet (CD) induced metabolic syndrome model in rats is selected as 
they more resemble to human ultra-processed diet compared to 
commercial high-fat or high-sugar rodent diets [35, 36]. The CD 
composed of condensed milk (8g), bread (8 g), chocolate (3 g), 
biscuits (6 g), dried coconut (6 g), cheese (8 g) and potato chips (10 
g). These diets were provided to the individual rats of group II to IV 
during the 42 d of the experiment. The calorie value of the CD 
indicated in (table 3). 
Experiment protocol 
The study includes 24 rats divided into four groups of 06 rats each. 
The drugs were administered through per oral (p. o.) route using 
oral gavage once a day for a period of 42 d. 
Group I: Normal control fed with rodent chow diet and 0.5% CMC. 
Group II: Fed with Cafeteria Diet. 
Group III: Cafeteria diet+Orlistat (45 mg/kg, p. o.) in 0.5% CMC from 
8th day. 
Group IV: Cafeteria diet+Anaglitin floating pellet formulation (200 
mg/kg, p. o.) from 8th day.  
The food intake of each animal group was measured by calculating 
the difference in weight of preweighed chows and the food remain 
over after 24 h. The daily caloric (kcal) intake was determined by 
multiplying the food intake by their caloric content and expressed as 
mean energy intake for a group of six rats in kcal/week. The body 
weights of the rats from each group were taken separately on 0th, 
7thand 42nd day. Body mass index (BMI) was calculated from 
formula: BMI = body weight (g)/length2 (cm2). On 43rd day animals 
were anesthetized with ether to collect the blood by the retro-orbital 
method. Serum was immediately separated by centrifuging at 4000 
rpm for 15 min
RESULTS AND DISCUSSION  
. The serum levels of glucose, total-cholesterol (CH), 
high-density protein (HDL), low-density protein (LDL), triglycerides 
(TGs), Alanine Aminotransferase (ALT) and Aspartate 
Aminotransferase (AST) were estimated using the biochemical kits 
(Pathozyme Diagnostics). After collection of blood, rats were 
sacrificed; organs viz; liver, heart and white adipose tissue (WAT) 
were excised immediately, rinsed with phosphate buffer saline and 
weighed.  
Statistical analysis 
Data were expressed as the mean±standard error of the mean 
(SEM). The results were analyzed by one way or two way ANOVA 
(analysis of variance) followed by Bonferroni test using Graph pad 
prism-7 software. Values of P<0.05 were considered significant. 
Design of gastroretentive floating pellets 
The floating system consisted of drug loaded pellets coated with 
three successive layers, release retardant Eudragit RS 100 as 
internal coat over which NaHCO3: HPMC E5LV layered as 
effervescent coat and gas entrapped Eudragit RL 100 as top coat 
indicated in (fig. 1). The prepared floating pellets were based on gas 
formation technique which upon contact with gastric fluid liberates 
carbon dioxide (CO2) due to the neutralization of NaHCO3. The 
liberated CO2 gets entrapped into the outer polymeric membrane 
and generates sufficient buoyancy to make the pellets float. The 
outer polymeric membrane should be highly water permeable so as 
to initiate the effervescent reaction and the floating process more 
rapidly. To maintain the flotation the hydrated coat should also be 
flexible to avoid rupturing and impermeable to the generated CO2 
[37]. Due to these reasons the higher flexible, water permeable and 
gas impermeable Eudragit RL 100 was chosen as a gas entrapped 
outer polymeric membrane. During effervescent layer coating as 
NaHCO3 itself is not sticky, HPMC E5 LV was used as binder to allow 
adherence of NaHCO3 on to the pellets. The solubility of anagliptin is 
higher in acidic media, it was difficult to sustain the release with 
Eudragit RL 100 and a release retarding polymer layer was required. 
Eudragit RS 100 was investigated as release retardant internal 
polymeric coat due to its lower hydrophilicity which makes it less 
water permeable. To develop an optimal formulation i.e. having 
minimum floating lag time and maximum drug release in 10 h, the 
parameters such as the concentration of Eudragit RS 100, the ratio of 
NaHCO3
 
Fig. 1: Design of gastroretentive floating pellets 
 
Evaluation of gastroretentive floating pellets 
Physical characterization 
To evaluate the flow properties of floating pellet formulations, Carr’s 
index, Hausner’s ratio and angle of repose were determined. The 
Carr’s index and Hausner’s ratio ranged from 5.22±0.31 % to 14.16
±0.15 % and 1.05±0.1 to 1.12±0.21 respectively. The values 
obtained for the angle of repose were in the range of 23.5
: HPMC and Eudragit RL 100 concentration were varied and 




Surface morphology of the uncoated and coated pellets are shown in 
(fig. 2). Fig. 2. (A) shows the surface of drug-containing uncoated 
pellets. The uncoated pellets exhibit rough external appearance. fig. 
2. (B) Eudragit RS 100 coated pellets shows the spherical shape and 
smooth surface. The effervescent layer coating over Eudragit RS 100 
coated pellets produce pellets with a slight smooth surface as 
indicated in fig. 2. (C). This may occur due to the layering of NaHCO
. The obtained data of micromeritic properties 
indicated good flow behavior of pellet formulation. The friability of 
the pellets formulation ranged from 0.24±0.11 % to 0.51±0.08 %. 
The results of friability study showed that the prepared core pellets 
were quite hard and suitable for the subsequent coating process. 
Pellet sphericity 
Sphericity of the pellets is an essential property to obtain effective 
coating. The spherical shape pellets provides uniform surface during 
the coating process. Sphericity of the pellets was determined in 
terms of aspect ratio. The aspect ratio values equal to unity indicate 
the spherical shape of pellets [24]. The prepared core pellets showed 
aspect ratio values in the range of 0.98±0.01 to 1.09±0.05. 
Drug content 
The drug content in all the floating pellet formulation was 
determined by UV spectroscopy method. It was found to be between 
96.23±0.5% to 98.75±0.41% which indicated that the multilayering 
coating on the pellets was uniform and it does not affect the drug 
content. 
Scanning electron microscopy (SEM) 
3 
 
dispersion (prepared in HPMC E5 LV solution). The top coat of 
Eudragit RL 100 as gas entrapped polymer coating (complete 
floating pellets) produces pellets with the smoothest surface shown 
in fig. 2. (D). 
Mishra et al. 





Fig. 2: Scanning electron microphotographs of (A) Drug loaded uncoated pellets, (B) Pellets coated with release retardant (5% Eudragit 
RS 100), (C) Effervescent layered (NaHCO3
 
Floating studies 
: HPMC; 2:1 w/w) coat over Eudragit RS 100 coat, (D) Gas entrapped complete floating pellets 
(5% Eudragit RL 100) 
The prepared anagliptin pellets was studied for gastro-floating 
behaviour in 0.1 N HCl. Floating lag time and the percentage of 
pellets floating at 10 h were determined. An ideal floating system 
after contact with gastric fluid should float in few seconds to avoid 
the formulation from transiting into small intestine [18]. The data 
obtained with floating studies revealed that the floating behaviour is 
significantly affected by the amount of effervescent agent (NaHCO3: 
HPMC ratio) and level of gas entrapped polymeric coating (Eudragit 
RL 100). In the present study the amount of effervescent layer 
coating was kept constant (10% w/w) and ratio of NaHCO3: HPMC 
was varied. The floating lag time observed for all pellet formulation 
was in the range of 3 to 35 min shown in (table 4). As the amount of 
NaHCO3 in effervescent layer coating increases and the level of 
Eudragit RL 100 coat decreases, the floating lag time gets decreased. 
This behaviour could be explained as, with lower level of Eudragit 
RL 100 coat the acidic media can quickly penetrates into the system 
and initiate effervescent reaction more rapidly. On the other side the 
lower level of Eudragit RL 100 with lower level of NaHCO3 unable to 
produce pellets with minimum floating lag time. This could be 
attributed due to the reduced amount of NaHCO3 with lower level of 
Eudragit RL 100 coat, the medium penetration was rapid but unable to 
generate sufficient CO2 to provide buoyancy. The percentage of pellets 
floating at 10 h ranged from 70% to 92% for all pellet formulation as 
shown in (fig. 3). The pellet formulations prepared with lower level of 
Eudragit RL 100 and higher level of effervescent agent also shows 
about 75% floating at 10 h. This indicated that even the lower amount 
of Eudragit RL 100 used in the study was sufficient to entrap the 
generated CO2 
 
and can maintain the floating for upto 10h. 
 
Fig. 3: Percentage pellets floating at 10 h of batches F 1 to F 13 mean±SD; n = 3 
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In vitro drug release study 
The in vitro release profile of anagliptin uncoated and coated floating 
pellet formulations were studied indicated in (fig.4). The uncoated 
anagliptin pellets showed about 80% drug release in 1 h. In the 
preliminary study the release profile of floating pellets (without 
Eudragit RS 100 release retardant coat) was also studied. Even the 
higher level of Eudragit RL 100 coat (15%) system also gives more 
than 75 % drug release in less than 2 h (data not shown), indicated 
Eudragit RL 100 alone unable to sustain the drug release. Afterward, 
it was decided to investigate Eudragit RS 100 as release retardant 
internal polymer layer to obtain sustain drug release for 10 h. As the 
amount of Eudragit RS 100 was increased the drug release was 
decreased. The result indicated that with increasing polymer layer 
thickness, medium penetration reduces leading to decreased drug 
release. However, no significant difference in drug release was 
observed by varying the amount of effervescent agent. The in vitro 
release studies reveals that with lower level of Eudragit RS 100 (5 
%) as release retardant, maximum drug release (about 85%) can be 
obtained in 10 h. 
  
Table 4: Response data of batches F1-F14 
Batch No. Floating lag time (min) Y Average drug release in 10 h (%) Y1 2 
F1 9.8±1.7 64.79±0.21 
F 2 17.9±2.1 68.58±0.15 
F 3 21.2±2.4 75.86±0.29 
F 4 13.4±1.3 84.88±0.34 
F 5 25.6±2.5 73.78±0.41 
F 6 6.4±1.9 79.85±0.23 
F 7 29.2±1.5 80.19±0.26 
F 8 29.4±3.2 56.24±0.33 
F 9 20.9±2.8 52.23±0.37 
F 10 3.6±1.2 73.29±0.22 
F 11 6.2±1.4 55.79±0.23 
F 12 33.6±2.5 65.57±0.24 
F 13 13.2±1.6 59.71±0.43 
F 14 3.4±1.5 86.54±0.35 
mean±SD; n = 3 
 
 
Fig. 4: In vitro dissolution study of uncoated and floating pellet formulations (batch F 1–F 14) mean±SD; n = 3 
 
Drug release data of floating pellets formulation (batch F 14) was 
analyzed according to various mathematical models to understand 
the drug release kinetics. The regression coefficients (R2) obtained 
from various models shown in (table 5). The R2
 
value was used as an 
indicator of the best fitted model suggested that the drug release 
follows either zero-order or Higuchi’s model. Both dissolution and 
diffusion from the surface of pellets were responsible for initial 
slight fast release. As the drug depleted in the outer zone, the drug 
particles in the inner area diffused with a slower rate through the 
coated polymer layer.  
Table 5: Regression coefficients of various mathematical models 
Batch No. Zero-order First order Higuchi release Korsmeyer-peppers 
F 14 0.9977 0.9811 0.9906 0.9899 
 
Statistical data analysis and optimization 
The responses obtained (floating lag time and drug release in 10 h) for 
13 batches were fitted into the various model using design expert 
software. A quadratic model is suggested for both the responses 
accordingly ANOVA for response surface quadratic model was 
generated indicated in (table 6). For the model to fit well with the 
experimental design the model p-value should be significant and the 
lack of fit should be insignificant [33]. The model F value and Prob>F 
values (less than 0.05) obtained for both the responses indicated that 
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the model terms are significant. Lack of fit for both the response was 
found to be not-significant indicated that the selected model can be 
suitably studied further for response surface plots. The ANOVA results 
suggested that for floating lag time (coded units B, C, A2, B2, C2 and BC) 
and drug release (coded units A, C, A2 and C2) are significant model 
terms (A: Eudragit RS 100; B: NaHCO3: HPMC and C: Eudragit RL 100). 
The values of SD, CV, R2, adjusted R2and predicted R2 are shown in 
(table 7). For both the responses the predicted R2value is in reasonable 
agreement with adjusted R2
 
 value. Adequate precision measures signal 
to noise ratio (>4 desirable). In both responses the adequate precision 
was greater than 4 indicating an adequate signal and the model can be 
used to navigate the design space. 
Table 6: Summary of ANOVA results for response surface quadratic model 
Parameter Sum of squares Degrees of freedom Mean square F value P value Prob>F Remark 
Floating lag time  
Model 1167.04 9 129.67 2951.87 <0.0001 significant 
Residual 0.31 7  0.044 
Lack of Fit 0.25 3  0.083 5.50 0.0666 not-significant 
Pure Error 0.060 4  0.015 
Drug Release in 10 h  
Model 1314.87 9 146.10 1131.47 <0.0001 significant 
Residual 0.90 7  0.13 
Lack of Fit 0.11 3 0.037 0.19 0.8986 not-significant 





Fig. 5: Response surface plot of floating lag time and average drug release in10 h 
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Table 7: Summary of statistical parameters for the responses 
Parameter Floating lag time Drug release in 10 h 
Mean 17.82 68.49 
SD 0.21 0.36 
CV 1.18 0.52 
R 0.9997 2 0.9993 
Adjusted R 0.9994 2 0.9984 
Predicted R 0.9965 2 0.9977 
Adeq Precision 188.959 117.944 
SD: Standard deviation; CV: Coefficient of variation 
 
The response surface plot obtained for the floating lag time and drug 
release in 10 h were indicated in (fig. 5). Response plot of floating lag 
time indicated a significant effect of the amount of effervescent agent 
(NaHCO3: HPMC ratio) and level of gas entrapped polymeric coating 
(Eudragit RL 100) on floating behaviour. Increasing the amount of 
effervescent agent and decreasing level of Eudragit RL 100 
decreases floating lag time. Eudragit RS 100 significantly affects drug 
release as shown by response plot of drug release in 10 h. The drug 
release decrease with increasing level of release retardant Eudragit 
RS 100 internal coat. The results can be correlated with the obtained 
regression equation also indicated below (A: Eudragit RS 100; B: 
NaHCO3: HPMC and C: Eudragit RL 100). It was observed from 
regression equation coefficients that (B: NaHCO3
Regression equations of the fiited quadratic model:  
: HPMC) and (C: 
Eudragit RL 100) had marked negative and positive effect on floating 
lag time respectively. The regression equation coefficients of average 
drug release in 10 h indicated a more pronounced negative effect of 
(A: Eudragit RS 100) and (C: Eudragit RL 100) on in vitro drug 
release. 




2-Avg. drug release (10 h) = 68.43-12.10A-0.26B–4.15C–
0.80A2+0.39B2+0.54C2
(fig. 6.) indicating the dignostic plot (predicted vs. actual) for both 
the responses. It can be seen from the plots that in all the cases there 
was a reasonable agreement between the predicted and 
experimental values. This confirms that the selected model for the 
current study adequately describes the influence of the independent 




Fig. 6: Correlation between actual and predicted values for (A) Floating lag time and (B) Drug release in 10 h 
 
Desirability approach under numerical optimization technique was 
used to prepare optimum formulation. The optimum formulation was 
obtained by applying constraints to independent and dependent 
variables (responses). Independent variables were kept in the range 
whereas floating lag time and percent drug release in 10 h set to 
minimum and maximum respectively. Nine solutions were generated 
by the design expert software among which one is selected having the 
highest desirability. The selected solution is indicated in (table 8). A 
new optimized formulation (batch F 14) indicated in table 2 was 
prepared and evaluated for the responses. The results of floating lag 
time and average drug release obtained of batch F 14 shown in table 4. 
The obtained experimental results of batch F 14 were in near 
proximity to the theoretical values of floating lag time and drug release 
in 10 h indicated by numerical optimization (table 8). 
 
Table 8: Summary of numerical optimization 
Parameters Goal Solution Desirability Remark 
Independent Variables 1 Selected 
Eudragit RL 100 in range -1 (5%) 
NaHCO3 in range : HPMC +1 (2:1) 
Eudragit RL 100 in range -1 (5%) 
Dependent Variables 
Floating lag time minimum 3.1 min 
Percent drug release in 10 h maximum 84.94 % 
 
Stability studies 
During stability studies, the floating pellet formulation is exposed to 
the accelerated condition of temperature and humidity for three 
months. At regular interval (1st, 2nd and 3rd month), the drug content, 
drug release at 10 h and physical appearance were studied. No 
significant changes in drug content and drug release were observed 
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during storage as indicated in (table 9). The physical appearance 
was also remain unchanged after three month. The data obtained 
with stability studies indicated that the developed multilayer 
floating pellet system of anagliptin was stable. 
 
Table 9: Accelerated stability study results for formulation (batch F 14) 
Month Appearance Drug Content (%) Drug release at 10 h (%) 
0 White 98.75±0.41 86.54±0.35 
1 White 98.24±1.01 85.49±0.98 
2 White 97.52±0.95 85.11±1.12 
3 White 96.16±1.29 84.04±1.67 
mean±SD; n = 3 
 
Pharmacokinetics in wistar rats 
The pharmacokinetic parameters were determined for F14 
anagliptin floating pellets in comparison to plain anagliptin drug. 
Anagliptin plasma concentrations comparison between floating 
pellets and plain drug were shown in (fig. 7). The calculated mean 
pharmacokinetic parameters were shown in (table 10). The change 
in Cmax and increase in Tmax values indicated sustained drug 
release of F14 floating pellets. A 2.51-fold increase in relative 
bioavailability of F14 anagliptin floating pellets compared to plain 
drug was observed. Higher half-life, MRT and lower elimination rate 
constant values indicated long resident time of anagliptin floating 
pellets. The statistical analysis revealed that there was a significant 
difference in the Cmax, Tmax, AUC, t1/2
 
, Kel and MRT. 
Table 10: Pharmacokinetics of anagliptin floating pellets and anagliptin plain drug 
Parameters F14 anagliptin floating pellets Anagliptin plain drug 
C max (μg/ml)  43.17±2.17* 30.51±2.83 
T max (h)  8.00±0.04* 0.5±0.04 
AUC0-∞ 376.15±7.55* (μg-h/ml)  149.86±6.43 
MRT (h)  9.07±0.03* 4.39±0.02 
t1/2 8.90±2.43* (h) 4.46±1.12 
Kel (h-1 0.18±0.11* ) 0.37±0.27 
Relative bioavailability: AUC of F14 Pellets/AUC of Plain drug=2.51 
*P<0.05 as compared to anagliptin plain drug, mean±SD; n = 6 
 
 
Fig. 7: Time versus mean plasma concentration profiles of anagliptin floating pellets and anagliptin plain drug mean±SD; n = 6 
 
Pharmacodynamics in Wistar rats 
Effect on calorie intake 
The calorie intake was significantly increased in the cafeteria diet-
fed rats (3086.05) as compared to the normal diet-fed rats 
(2108.45). However, the rats received anagliptin floating pellets and 
orlistat showed a significant decrease in calorie intake per week 
(2283.99, 1890.18) respectively indicated in (fig. 8). 
Effect on body weight and BMI 
The animal group fed with CD for six weeks showed a significant 
increase in body weight and BMI (277.98±3.69, 2.65±0.03) 
compared the normal diet-fed rats (212.20±2.63, 1.41±0.04) 
shown in (fig. 9 and 10). Treatment with anagliptin floating pellets 
and orlistat significantly reduced the increased in body weight and 

























Fig. 8: Effect on calorie intake, values are mean±SEM, 
n=6, ##P<0.01 as compared to normal control, ***P<0.001, 
*P<0.05 as compared to cafeteria diet group using one way 
ANOVA followed by Bonferroni test 
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Fig. 9: Effect on body weight, values are mean±SEM, 
n=6, ####P<0.0001 as compared to normal control, ***P<0.001 
as compared to cafeteria diet group on 42nd
The serum levels of glucose, CH, LDL, TGs, ALT and AST were found 
to be significantly increased in the cafeteria diet-fed rats compared 
to the normal diet-fed rats. On the contrary HDL level was found to 
be significantly decreased in CD control group. However, anagliptin 
treatment significantly reduced the increase in serum levels of 
glucose, CH, LDL, TGs, ALT and AST and increased HDL 
concentration significantly as indicated in (table 11). 
 day using two way 
ANOVA followed by Bonferroni test 
 


























Fig. 10: Effect on BMI, values are mean±SEM, n=6, ####
 
P<0.0001 as 
compared to normal control, ***P<0.001 as compared to cafeteria 
diet group using one way ANOVA followed by bonferroni test 
Table 11: Effect of anagliptin treatment on serum biochemical parameters 
Parameters Normal Cafeteria Diet Orlistat Anagliptin 
Glucose (mg/dl) 68.89±0.45 107.13±0.92 80.82±1.19#### 74.82±1.07*** **** 
CH (mg/dl) 66.06±1.57 110.04±1.31 80.93±1.51#### 95.19±0.61*** 
LDL (mg/dl) 
** 
37.94±1.02 55.89±1.17 39.81±0.95### 46.29±1.31*** 
TGs (mg/dl) 
** 
63.95±0.85 105.99±1.29 75.43±1.56#### 96.12±1.25*** 
ALT (u/l) 
** 
41.36±0.63 83.93±0.41 56.92±0.41#### 66.04±0.77*** 
AST ((u/l)) 
** 
58.02±0.48 103.52±0.62 62.80±0.69#### 71.92±0.45*** 
HDL (mg/dl) 
*** 
47.67±1.45 30.92±0.77 49.04±1.71### 42.15±0.92*** ** 
Values are mean±SEM, n=6, ####P<0.0001, ###
 
P<0.001 as compared to normal control, ***P<0.001, **P<0.01 as compared to cafeteria diet group. 
Table 12: Effect of anagliptin treatment on organs weight 
Organs Normal Cafeteria diet Orlistat Anagliptin 
Liver (g) 7.34±1.15 14.06±1.24 8.25±1.11#### 9.40±1.24*** *** 
Heart (g) 1.22±0.46 2.70±0.54 1.68±0.49### 2.03±0.61*** 
WAT (g) 
** 
3.65±0.87 8.48±1.16 4.13±0.63#### 4.97±0.44*** *** 
Values are mean±SEM, n=6, ####P<0.0001, ###
 
P<0.001 as compared to normal control, ***P<0.001, **P<0.01 as compared to cafeteria diet group. 
Effect on organ weight and WAT 
The CD control group showed a significant increase in the weight of 
organs and white adipose tissue as compared to normal control shown 
in (table 12). Treatment with anagliptin significantly decreased organs 
weight and white adipose tissue which were induced by cafeteria diet. 
CONCLUSION 
The anagliptin gastroretentive floating pellets based on gas 
formation technique was successfully designed and developed. From 
the numerical optimization function using Design expert software, 
an optimal formulation (F 14) comprising of Eudragit RS 100 (5%), 
sodium bicarbonate: HPMC (2:1) and Eudragit RL 100 (5%) was 
identified. It showed floating lag time of 3.4 min and 86.54% drug 
release at 10 h. The pharmacokinetic study conducted in male 
Wistar rats showed increased Cmax, prolonged Tmax, half-life and 
MRT collectively demonstrated sustained drug release. The relative 
bioavailability of optimized formulation was improved by 2.51 fold 
in comparison to anagliptin drug. The results of anagliptin floating 
pellets treatment in male Wistar rats fed on cafeteria diet showed its 
hypophagic, hypoglycemic and hypolipidemic effects. The gastro-
retentive floating pellets of anagliptin with improved bioavailability 
was obtained and could be promisingly used in the management of 
the metabolic syndrome.  
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